[go: up one dir, main page]

PE20080099A1 - Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion y composiciones que las contienen - Google Patents

Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion y composiciones que las contienen

Info

Publication number
PE20080099A1
PE20080099A1 PE2007000625A PE2007000625A PE20080099A1 PE 20080099 A1 PE20080099 A1 PE 20080099A1 PE 2007000625 A PE2007000625 A PE 2007000625A PE 2007000625 A PE2007000625 A PE 2007000625A PE 20080099 A1 PE20080099 A1 PE 20080099A1
Authority
PE
Peru
Prior art keywords
trihydroxy
alcoxy
alkyl
enamide
tetrahydro
Prior art date
Application number
PE2007000625A
Other languages
English (en)
Inventor
Jidong Zhang
Yannick Benedetti
Alain Commercon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20080099A1 publication Critical patent/PE20080099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-ALCOXI-3,4,5-TRIHIDROXI-ALQUILAMIDA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C12), ALQUENILO(C2-C12), ALQUINILO(C2-C12), CICLOALQUILO, ENTRE OTROS; R2 ES ALQUILO(C1-C6), ARILO, ALCOXI(C1-C6)-ALQUILO(C1-C6), ENTRE OTROS; R3 ES H, COO(R5), CO(R5), R5, ENTRE OTROS, DONDE R5 ES H, ALQUILO(C1-C12), ALQUENILO(C2-C12), ALQUINILO(C2-C12), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON OH, HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS SUSTITUYENTES; R4 ES H, F, Cl, NO2, CN, ENTRE OTROS; X1 ES CH2; X2 ES O, N(R5) O X1 Y X2 FORMAN JUNTOS -N=C(R5)- O -N(R5)-C(R5)(R5)-; m ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-((S)-8-OXO-6,7,8,9-TETRAHIDRO-5-OXA-9-AZA-BENZOCICLOHEPTEN-7-IL)-(E)-(2R,3R,4S,5R)-3,4,5-TRIHIDROXI-2-METOXI-8,8-DIMETIL-NON-6-ENAMIDA, N-((S)-9-METIL-8-OXO-6,7,8,9-TETRAHIDRO-5-OXA-9-AZA-BENZOCICLOHEPTEN-7-IL)-(E)-(2R,3R,4S,5R)-3,4,5-TRIHIDROXI-2-METOXI-8,8-DIMETIL-NON-6-ENAMIDA, N-((S)-2-OXO-2,3,4,5-TETRAHIDRO-1H-1,5-BENZODIAZEPIN-3-IL)-(E)-(2R,3R,4S,5R)-3,4,5-TRIHIDROXI-2-METOXI-8,8-DIMETIL-NON-6-ENAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTICANCERIGENOS
PE2007000625A 2006-05-24 2007-05-21 Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion y composiciones que las contienen PE20080099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604736A FR2901556A1 (fr) 2006-05-24 2006-05-24 Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
PE20080099A1 true PE20080099A1 (es) 2008-03-31

Family

ID=37561171

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000625A PE20080099A1 (es) 2006-05-24 2007-05-21 Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion y composiciones que las contienen

Country Status (24)

Country Link
US (1) US7994161B2 (es)
EP (1) EP2029555A2 (es)
JP (1) JP2009537616A (es)
KR (1) KR20090010215A (es)
CN (1) CN101454296B (es)
AR (1) AR061105A1 (es)
AU (1) AU2007253198A1 (es)
BR (1) BRPI0712264A2 (es)
CA (1) CA2649685A1 (es)
CR (1) CR10390A (es)
DO (1) DOP2007000105A (es)
EA (1) EA200870567A1 (es)
EC (1) ECSP088899A (es)
FR (1) FR2901556A1 (es)
GT (1) GT200800252A (es)
IL (1) IL195053A0 (es)
MA (1) MA30496B1 (es)
MX (1) MX2008015003A (es)
NO (1) NO20085267L (es)
PE (1) PE20080099A1 (es)
TN (1) TNSN08411A1 (es)
TW (1) TW200812981A (es)
UY (1) UY30367A1 (es)
WO (1) WO2007135295A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477464A (en) * 1983-02-10 1984-10-16 Ciba-Geigy Corporation Hetero-benzazepine derivatives and their pharmaceutical use
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) * 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6239127B1 (en) * 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
CO5140099A1 (es) * 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
DE60132324T2 (de) 2000-05-11 2008-12-24 Novartis Ag Substituierte caprolactam carbonate und ether sowie deren verwendung als anti-tumor wirkstoffe
AU2002217020A1 (en) 2000-11-14 2002-05-27 Novartis Ag Method for screening anti-proliferative compounds and inhibiting tumor growth
US6545148B2 (en) * 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
MXPA06000975A (es) * 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US7153846B2 (en) * 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
FR2878528B1 (fr) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
FR2878525B1 (fr) * 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
CA2649685A1 (fr) 2007-11-29
EA200870567A1 (ru) 2009-06-30
CR10390A (es) 2009-01-09
UY30367A1 (es) 2008-01-02
CN101454296A (zh) 2009-06-10
IL195053A0 (en) 2009-08-03
EP2029555A2 (fr) 2009-03-04
MA30496B1 (fr) 2009-06-01
BRPI0712264A2 (pt) 2012-01-17
KR20090010215A (ko) 2009-01-29
DOP2007000105A (es) 2007-11-15
MX2008015003A (es) 2008-12-09
AU2007253198A1 (en) 2007-11-29
JP2009537616A (ja) 2009-10-29
GT200800252A (es) 2009-03-13
FR2901556A1 (fr) 2007-11-30
CN101454296B (zh) 2011-11-09
TW200812981A (en) 2008-03-16
US7994161B2 (en) 2011-08-09
ECSP088899A (es) 2008-12-30
US20090075971A1 (en) 2009-03-19
WO2007135295A2 (fr) 2007-11-29
TNSN08411A1 (en) 2010-04-14
NO20085267L (no) 2009-02-23
AR061105A1 (es) 2008-08-06
WO2007135295A3 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
UA98966C2 (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
EA201001556A1 (ru) Соединения, включающие противовоспалительный фармакофор, и способы их применения
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR055878A1 (es) Derivados de ciclopropanocarboxamida
NO20071476L (no) Antidiuretiske midler.
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
SE0403171D0 (sv) New compounds
AR060379A1 (es) Compuesto y composicion herbicida
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии

Legal Events

Date Code Title Description
FC Refusal